Redeye provides an update following SciBase’s Q2 2026 report. We argue that the company continues to progress well, as reflected in the strong sales growth. Costs came in higher than expected, and it is clear that the company will need to raise capital in the near term. We remain positive on the company’s outlook despite slightly lowering our sales estimates. Furthermore, we introduce our new fair value, which suggests that the SciBase share is currently “cheap”.
LÄS MER
